Xtant Medical Reports 35% Revenue Decline and $9.4 Million Net Loss in Q2 2026

Xtant Medical Holdings, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenue of $23.0 million, down 35% from $35.4 million in the same period of 2025. For the first half of 2026, revenue decreased by 36% to $43.9 million compared to $68.3 million in the prior year. The company attributed these declines primarily to the loss of revenue from the divestiture of its Coflex and CoFix products, which accounted for $5.6 million and $11.0 million in revenue for the three and six months ended June 30, 2025, respectively. Additionally, a decrease in licensing revenue, which fell by $5.0 million and $8.6 million in the respective periods, further impacted overall revenue.

The company reported a net loss of $9.4 million for the second quarter of 2026, compared to a net income of $3.6 million in the same quarter of 2025. For the first half of 2026, the net loss was $12.5 million, contrasting with a net income of $3.6 million in the prior year. The loss was exacerbated by a $5.0 million charge related to an exclusivity fee paid to Dilon Technologies, which was recognized as an operating expense due to uncertainty regarding its recoverability. Operating expenses for the quarter totaled $22.5 million, up from $19.7 million in the previous year, driven by increased costs associated with the Dilon distribution agreement and the write-off of the exclusivity fee.

In terms of operational developments, Xtant Medical has made strategic moves to enhance its market position. In April 2026, the company entered into a distribution agreement with Dilon Technologies, granting it exclusive rights to market and sell the HEMOBLAST® Bellows product in the U.S. This agreement led to the hiring of approximately 20 sales personnel to support the product's launch. However, the company faces risks associated with relying on Dilon for manufacturing and supply, as it does not control the production process. The company also completed the sale of its non-core assets to Companion Spine, generating $21.4 million in proceeds, which were partially used to reduce long-term debt.

As of June 30, 2026, Xtant Medical reported total assets of $79.7 million, down from $94.1 million at the end of 2025. Current liabilities increased slightly to $30.0 million, while total liabilities decreased to $39.7 million. The company’s cash and cash equivalents stood at $9.9 million, a decrease from $17.1 million at the end of 2025. The company’s employee headcount increased to support its new distribution agreement, but the overall financial outlook remains cautious due to the anticipated continued impact of lost revenue from divestitures and changes in the reimbursement environment.

Looking ahead, Xtant Medical anticipates ongoing challenges in achieving revenue growth, particularly in light of the significant declines in product and licensing revenues. The company is focused on integrating the HEMOBLAST® Bellows product into its portfolio and leveraging new sales personnel to drive growth. However, uncertainties surrounding the supply chain and the effectiveness of its new sales strategy may hinder its ability to return to profitability in the near term. The company has indicated that it may seek additional financing to support its operations and strategic initiatives, depending on market conditions and its financial performance.